.Charles Baum, M.D., Ph.D., who managed Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2015, is taking the helm of young biotech Terremoto Biosciences.Baum's "significant adventure in medicine progression, as well as established record in advancing high-impact medicines, will definitely contribute," outbound CEO Peter Thompson, M.D., stated in a July 25 release. Thompson will preserve his seat as board chairperson..Baum, a competent physician-scientist, was the creator, head of state as well as CEO of oncology-focused Mirati. Just before that, he helped create cancer cells medicines at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum will act as CEO at Terremoto, a provider creating little particles to target disease-causing proteins-- like those found in harmful cyst tissues-- utilizing covalent connects. Existing therapies that utilize covalent bonds largely target the amino acid cysteine. However, of the 20 amino acids that compose healthy proteins, cysteine is the least usual. Terremoto is rather targeting among the necessary amino acids, lysine, which is discovered in mostly all proteins.Through targeting amino acid lysine and also various other amino acids, Terremoto wishes to handle earlier undruggable health conditions as well as make first-in-class medicines..The biotech, located in South San Francisco, reared $75 thousand in series A funding in 2022. A little bit of much more than a year later on, the biotech more than multiplied that number in a $175 thousand set B.